Phase 2 Trial of Pembrolizumab-Based Therapy in Previously Treated Extrapulmonary Poorly-Differentiated Neuroendocrine Carcinomas: Results of Part B (Pembrolizumab Plus Chemotherapy)

PANCREAS(2022)

引用 0|浏览16
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要